Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiovascular risks
Biotech
Silence says its drug lowers levels of heart disease risk factor
Silence Therapeutics plans to take its siRNA drug into a phase 2 study in patients with a certain heart disease after phase 1 data showed promise.
Kyle LaHucik
Feb 9, 2022 1:50pm
Lilly's tirzepatide aces 5th phase 3, teeing up filings
May 20, 2021 8:16am
Roche broadens blood test reach with sweeping new use claims
Apr 28, 2021 11:03am
Prevencio rolls out AI-powered blood tests for heart disease
Apr 22, 2021 12:14pm
FDA warns of death risk linked to SynCardia heart pump
Aug 22, 2018 10:55am
Boston Scientific buys cryoablation firm Cryterion for $202M
Jul 6, 2018 10:50am
